Amgen to Withdraw the ABP 710 (biosimilar, infliximab) MAA with European Medical Agency

Amgen to Withdraw the ABP 710 (infliximab, biosimilar) MAA with European Medical Agency

Shots:

  • The MAA’s withdrawal is in response to the change in European product strategy for ABP 710. Additionally, Amgen will focus on the resources the most value for patients can be provided
  • In Dec 2018, Amgen has also submitted BLA for ABP 710 to the US FDA and has two more biosimilars under development ABP 798 (rituximab, biosimilar) and ABP 959 (eculizumab, biosimilar)
  • ABP 710 (100 mg powder) is a mAb anti-inflammatory drug targeted to treat rheumatoid arthritis, Crohn’s disease, ulcerative colitis, including ankylosing spondylitis, psoriatic arthritis, and psoriasis

Click here to read full press release/ article | Ref: EMA | Image: Twitter